Millions of people across the globe begin their professional duties long before the sun rises, fighting a biological battle against their own internal clocks. For those starting shifts in the pre-dawn hours, the struggle is often more than just a lack of sleep; This proves a clinical challenge known as shift work disorder (SWD). A recent clinical trial now suggests that a specific wake-promoting medication could provide a vital treatment for early-morning shift work disorder, allowing workers to remain alert and safe on the job.
The study, led by researchers at Mass General Brigham, focused on the specific challenges faced by those who start their workday between 3 a.m. And 7 a.m. While much of the existing research on shift work has historically focused on overnight schedules, this trial addresses a significant gap in medical literature by targeting the most common type of shift schedule. The findings, published in NEJM Evidence, indicate that the drug solriamfetol can significantly boost alertness and improve overall daily performance for those struggling with excessive sleepiness.
For the millions of workers in healthcare, logistics, and emergency services who operate on these schedules, the implications are substantial. Fatigue-related mistakes in these sectors can lead to severe safety risks. By improving concentration and productivity, this pharmacological intervention may reduce the incidence of errors and enhance the quality of life for those whose careers require them to work against their natural sleep cycles.
The Clinical Trial: Testing Solriamfetol for Early-Morning Shifts
The research was designed as a randomized, double-blind, placebo-controlled trial to ensure the highest level of scientific rigor. The study included 78 early-morning shift workers who met the clinical criteria for shift work disorder and experienced excessive sleepiness. To isolate the effects of the drug, participants were divided into two groups: one receiving solriamfetol and the other receiving a placebo.
Participants in the trial took the medication on each of their workdays over a four-week period. The trial specifically targeted individuals whose shifts began between 3 a.m. And 7 a.m., a window where the body’s circadian rhythm is typically at its lowest point of alertness, often referred to as the “circadian trough.”
The results showed that those who took solriamfetol were better able to stay awake and function throughout their full shifts. Beyond simply staying awake, the researchers noted improvements in productivity, safety, and general daily performance. This suggests that the drug does not merely mask tiredness but helps the brain function more effectively despite the biological misalignment of the worker’s schedule.
Understanding the Mechanism: How the Drug Works
Solriamfetol, marketed under the brand name Sunosi, is classified as a selective dopamine and norepinephrine reuptake inhibitor. Unlike traditional stimulants, it works by increasing the levels of these two key neurotransmitters in the brain, which are essential for maintaining wakefulness and cognitive focus. By preventing the reabsorption of dopamine and norepinephrine, the drug helps sustain a state of alertness that is typically absent during the early morning hours for those with SWD.
Shift work disorder occurs when there is a misalignment between an individual’s internal biological clock (the circadian rhythm) and the external requirements of their work schedule. For early-morning workers, the brain is often still in a “sleep state” when the alarm goes off, leading to severe fatigue, impaired concentration, and a higher risk of workplace accidents. Solriamfetol acts as a pharmacological bridge, helping the brain transition into an active state more effectively.
Key Findings at a Glance
| Metric | Observation |
|---|---|
| Participant Count | 78 early-morning shift workers |
| Study Duration | Four weeks of workday administration |
| Primary Benefit | Significant boost in alertness and wakefulness |
| Secondary Benefits | Improved productivity, safety, and daily performance |
| Target Shift Window | Starts between 3 a.m. And 7 a.m. |
Closing the Research Gap in Circadian Medicine
One of the most critical aspects of this study is its focus on early-morning workers rather than overnight workers. For years, the medical community has focused on the “graveyard shift,” yet the early-morning start is far more common across various industries. This discrepancy left millions of workers without evidence-based treatment options for their specific type of circadian disruption.
Charles A. Czeisler, PhD, MD, the senior author of the study and chief and senior physician of the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine, emphasized the importance of this focus. Dr. Czeisler noted that until this trial, no clinical study had tested a treatment specifically for shift work disorder in early-morning workers, despite it being the most common shift schedule.
By addressing this gap, the research provides a roadmap for how healthcare providers can treat a vast population of workers who have previously been told that their fatigue was simply an inevitable part of their job. The ability to clinically treat excessive sleepiness in this group has the potential to transform workplace safety standards and employee wellbeing on a global scale.
What This Means for the Global Workforce
The implications of this study extend beyond the individual worker. In industries where precision and alertness are non-negotiable—such as surgery, aviation, and heavy machinery operation—the reduction of fatigue-related mistakes is a matter of public safety. When a worker’s brain is not “ready” for the day, the risk of cognitive lapses increases exponentially.
However, pharmacological treatments are typically intended to complement, not replace, healthy sleep hygiene. While solriamfetol can help maintain alertness during the shift, the long-term management of shift work disorder often involves a combination of light therapy, strategic napping, and consistent sleep schedules where possible.
As this treatment for early-morning shift work disorder becomes more widely recognized in clinical settings, the focus will likely shift toward how to integrate these medical interventions with occupational health policies. Employers may need to consider how to support workers who require medical assistance to manage the biological toll of early-morning schedules.
Key Takeaways
- Target Population: The study specifically helped workers starting shifts between 3 a.m. And 7 a.m.
- Proven Efficacy: Solriamfetol significantly improved alertness, productivity, and safety over a four-week period.
- Medical Mechanism: The drug works as a selective dopamine and norepinephrine reuptake inhibitor.
- Filling a Gap: What we have is the first clinical trial to specifically target early-morning shift workers rather than overnight workers.
- Safety Impact: Improved alertness can lead to a reduction in fatigue-related workplace errors.
With the publication of these findings in NEJM Evidence, the medical community now has a verified baseline for treating early-morning SWD. The next step for clinicians and researchers will be to determine the long-term sustainability of these results and to establish standardized dosing protocols for different industries.
We encourage readers to share this article with colleagues or loved ones who struggle with early-morning schedules. If you have experience managing shift work disorder, we invite you to share your thoughts in the comments below.